Bern Pollock uses close to 10 products from different manufacturers to manage his urostomy after bladder cancer. He explains why Medicare bidding concerns him.
|Articles|September 23, 2019
Prostate Cancer Awareness Month: What You Need to Know
Author(s)Jessica Skarzynski
For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
Advertisement
For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space:
- Following the Food and Drug Administration’s recent approval of Nubeqa (darolutamide), men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.
- Newly diagnosed? This piece gathers the best advice about prostate cancer from the men and families who have already gone through it.
- Men with advanced prostate cancer may benefit from genomic testing as BRCA and other gene mutations play a bigger role in guiding treatment.
- After taking up running at age 63, Andy Steinfeldt was diagnosed with prostate cancer a few years later. But he didn’t let it slow him down. Listen to our podcast interview with Andy, who looks at cancer “as a motivation rather than a destination."
- The Prostate Cancer Foundation recently announced a host of new free resources for patients and their families to ensure they can make the best treatment choices.
Advertisement
Related to this article
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
A metastatic breast cancer survivor shares how exercise gave her a sense of control while emphasizing why it should never be used to blame people with cancer.
A long-term metastatic ovarian cancer survivor explains how a trifecta of hope, purpose and grace has shaped her life through years of treatment.
Six-year PERSEUS results show 81% of newly diagnosed, transplant-eligible myeloma patients had no cancer progression, with many stopping Darzalex.
A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.
Living with metastatic breast cancer can make Pinktober feel complicated. One patient reflects on awareness, research, loss and remembering the people behind the pink.
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Advertisement
Advertisement
Trending on CURE
1
Phase 3 Trial Shows Adding Imdelltra to First-Line Treatment Helps Patients With SCLC Live Longer
2
Six Years Later, Most Myeloma Patients on a Darzalex Regimen Are Still Progression-Free
3
5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
4
10 Cancer Treatment Approvals From September 2026 and What They Mean for You
5